Insitro
Contact SalesML-native biotech decoding biology to accelerate drug development.
By Tanmay Verma, Founder · Last verified 26 May 2026
4.1k views
Added 4/3/2026
76/100Safe BetML-native biotech decoding biology to accelerate drug development.
By Tanmay Verma, Founder · Last verified 26 May 2026
Affiliate disclosure: We earn a commission when you use our links. Editorial picks are independent. How we choose.
Insitro is a serious ML-native biotech with a data-driven platform that integrates cellular and clinical data. Led by Daphne Koller, it has strong scientific leadership and partnerships (e.g., BMS). However, it remains a partner-dependent drug developer with no approved drugs yet. If you're a pharma company seeking AI-driven target discovery, insitro is a compelling collaborator; if you need a software product or short-term returns, look elsewhere.
Compare with: Insitro vs Quibim, Insitro vs Qualtrics XM, Insitro vs Nimbus Therapeutics
Last verified: May 2026
Insitro differentiates itself by building a full-stack, modality-agnostic AI platform through internal development and strategic acquisitions (CombinAbleAI, 2025). Its TherML engine unifies design across drug modalities. The company's focus on high-throughput cellular data and human genetics (e.g., brown fat study for obesity) demonstrates a strong data flywheel. Recent leadership hires (Joe Hand as CPO) and scientific advisors (Stephen Hitchcock, Vijay Pande) signal scaling ambitions. Weaknesses: no approved drugs, dependency on pharma partnerships for revenue, and limited public transparency on pipeline progress. Best suited for pharma R&D leaders, less so for small biotechs or investors seeking near-term exits.
Skip Insitro if Skip Insitro if you need a ready-to-deploy AI SaaS tool or have a limited budget for drug discovery collaborations.
AI-enabled BAT phenotype study; BAT-01 knockdown drives 15% weight reduction preserving lean mass.
Insitro uses AI to study brown adipose tissue genetics, yielding 15% body-weight reduction in preclinical models via BAT-01.
How likely is Insitro to still be operational in 12 months? Based on 6 signals including funding, development activity, and platform risk.
Insitro is a drug discovery and development company that uses machine learning and large-scale data to decode biology and create transformative medicines. Unlike traditional biotechs, insitro integrates in vitro cellular data with human clinical data through its proprietary ML platform, enabling systematic and data-driven drug design. The company focuses on metabolism, oncology, and neuroscience, with a pipeline of wholly-owned and partnered programs. In 2025, insitro launched TherML, a unified AI engine for therapeutic design across small molecules, biologics, and oligonucleotides, and acquired CombinAbleAI to complete its modality-agnostic platform. Key collaborations include an expanded partnership with Bristol Myers Squibb targeting ALS. Insitro is led by CEO Daphne Koller and serves pharma partners, not individual subscribers.
Tell us what you want to build — we'll match the AI tools that fit your goal, budget & existing stack.
Concrete scenarios for the personas Insitro actually fits — and what changes day-one when you adopt it.
You need to identify novel targets for a neurodegenerative disease program.
Outcome: Insitro uses its AI Virtual Human platform to nominate 2-3 validated targets from human genetics and cellular assays, accelerating preclinical timeline by 12-18 months.
You want to expand your pipeline into metabolic disorders but lack ML capabilities.
Outcome: Insitro's TherML engine designs a first-in-class small molecule for a validated target from its brown fat genetics study, with in vivo efficacy data showing 15% weight reduction.
Insitro is a partner-dependent drug developer, not a software product. You cannot buy a subscription; access requires a strategic collaboration. No public pricing or free tier exists. The platform is focused on pharma-scale problems, making it inaccessible for smaller entities. As of 2026, no drug developed by insitro has received FDA approval.
Project the real annual outlay, including the implied monthly cost when only an annual tier is published.
Vendor list price only. Add-on usage, seat overages, and contract minimums are surfaced under Hidden costs & gotchas.
For each published Insitro tier: who it actually fits, and what it adds vs. the previous tier. Cross-reference the cost calculator above for projected annual outlay.
Partnership
Custom
Ideal for
Large pharma companies with billion-dollar R&D budgets and strategic interest in AI-driven drug discovery across metabolism, oncology, or neuroscience.
What this tier adds
This is the only tier available; it involves custom contracts, milestone payments, and potential royalty sharing. No self-serve or subscription.
The company stage and team size where Insitro's pricing actually pencils out — and where peers do it cheaper.
Insitro's pricing is entirely custom, targeting large pharma partners. There is no free tier or small-scale entry point—suited only for organizations with substantial R&D budgets. Compared to AI software vendors, insitro is a high-investment, high-risk, high-reward partnership.
How long it actually takes to get something useful out of Insitro — broken out by persona, not the marketing-page minute.
For pharma partners, initial target nomination collaboration typically takes 3-6 months to align on data sharing and validation. Internal platform integration for in-house programs is ongoing; no instant setup.
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
Pricing, brand, ownership, or deprecation changes worth knowing before you commit. Most-recent first.
At insitro, our mission is to bring better drugs faster to the patients who can benefit most. Through the power of machine learning (ML) and data at scale, we decode the complexities of biology to unlock transformative new medicines.
By aggregating high-content data at scale and interpreting it through machine learning, insitro translates nebulous human biology into a clearer, more complete picture—allowing us to more accurately define diseases, identify effective therapies, and deliver them to patients who c
Common stack mates teams adopt alongside Insitro, with the specific reason each pairing earns its keep.
Used Insitro? Help shape our editorial sentiment research.
© 2026 RightAIChoice. All rights reserved.
Built for the AI community.
TherML unifies therapeutic design across all major drug modalities, addressing misalignment between target and therapy.
Last calculated: May 2026
The insitro platform powers the discovery of new medicines for a range of therapeutic areas. We prioritize our efforts toward diseases with significant unmet needs.
Designing highly selective small molecule medicines for oncology, immunology, and metabolism.
